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Abstract
Betel quid (BQ)–chewing oral cancer is a prevalent disease in many countries of Southeast Asia. Yet, the precise
disease mechanism remains largely unknown. Here, we show that BQ extract–induced cell motility in three oral
cancer cells (Ca9-22, SAS, and SCC9) presumably involves the Src family kinases (SFKs). Besides, BQ extract can
markedly induce cell migration of wild type mouse embryonic fibroblasts (MEFs) but not MEFs lacking three SFK
members, namely, Src, Yes, and Fyn, indicating the requirement of SFKs for BQ-induced cell motility. Betel quid
extract can also elevate cellular SFK activities because phosphorylation of tyrosine 416 at the catalytic domain is
increased, which in turn promotes phosphorylation of an in vitro substrate, enolase. Furthermore, we identified
that areca nut, a major component of BQ, is the key factor accounting for BQ-induced cell migration and invasion
through SFKs-mediated signaling pathways. Immunohistochemistry revealed that, particularly in BQ-chewing cases,
the activity of SFKs was significantly higher in tumor-adjacent mucosa than that in solid tumor areas (P < .01).
These results suggest a possible role of SFKs in tumor-host interface and thus in early tumor invasion in vivo.
Consistent with this is the observation that activation of SFKs is colocalized with invasive tumor fronts in oral squa-
mous cell carcinoma. Together, we conclude that SFKs may represent a potential biomarker of invasion and ther-
apeutic target in BQ-induced oral cancer.
Neoplasia (2008) 10, 1393–1401
Introduction
Betel quid (BQ) generally consists of areca nut (AN), inflorescence
of Piper betle (IPB) and slaked lime (SL). Betel quid chewing has been
widely practiced in many parts of Southeast Asian countries and Asian-
migrant communities elsewhere, adding up to a total of 600 million
BQ chewers worldwide [1]. In Taiwan, the incidence of oral cancer
death has been steadily increasing during the past decade. According
to recent statistics by the Department of Health, oral cancer deaths
have become the fourth common cause of overall cancer death in Tai-
wanese male population. It has been well documented that the high
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incidence of oral cancer death correlates intimately with BQ chewing
[2,3]. In fact, mounting evidence indicates a causative relationship be-
tween BQ chewing and carcinogenesis of oral squamous cell carcinoma
(OSCC) [1,4,5]. Despite mainly epidemiologic evidence, a recent re-
port by the International Agency for Research on Cancer further con-
firmed that BQ without tobacco and AN alone are sufficient to cause
carcinogenic effects in human [6]. However, the molecular mechanisms
of BQ-induced oral carcinogenesis remain virtually unknown.
Substantial research efforts have been made in an attempt to illu-
minate how BQ chewing could lead to oral carcinogenesis. For ex-
ample, it has been shown that AN extract and arecoline, one of the
AN alkaloids, can induce mutagenic and genotoxic effects in vitro [7–
9]. Also, BQ ingredients have been demonstrated to induce reactive
oxygen species and inflammatory mediators such as prostaglandins
[10,11], two critical factors thought to promote chemical carcinogen-
esis. Noticeably, two recent reports went further to verify that AN
ingredients can activate mitogen-activated protein kinases in oral ker-
atinocytes, leading to the induction of inflammatory mediators and
other stress responses such as activation of NF-κB signaling pathway
[12,13]. There are, however, rather limited studies that directly link
BQ ingredients–induced cellular responses to cancer-specific pheno-
types during the course of multistep chemical carcinogenesis.
Squamous cell carcinoma is the most common malignant neo-
plasm of the oral cavity, in that metastasis to cervical lymph nodes
of the neck is the most important prognostic indicator [14]. Invasion
or metastasis of OSCC requires active cell migration through the
extracellular matrix with simultaneous remodeling of intercellular ad-
hesions. This process is primarily assisted by up-regulation of the
extracellular matrix–degrading enzymes matrix metalloproteinases
(MMPs), in particular MMP-2 and MMP-9, and disruption of
cell-cell adhesion such as methylation of E-cadherin and degradation
of β-catenin [15–17]. Interestingly, previous studies by others sug-
gest that galectins, especially galectin-7, could promote cancer cell
migration of head and neck squamous cell carcinomas through up-
regulating the expression of MMP-9 [18,19]. In addition, there is
increasing evidence that overexpression of epidermal growth factor
receptor (EGFR) is correlated with oral cancer metastasis [20]. How-
ever, whether BQ ingredients might affect oral cancer cell behavior
such as invasion and/or metastasis is still unclear. Here, we report
that BQ and AN extracts can both significantly induce oral cancer
cell migration and invasion in vitro presumably through activation
of the Src family kinases (SFKs). Notably, AN seems to be the key
factor of the three major BQ components responsible for these bio-
logic effects. Moreover, our immunohistochemical analyses suggest
that the activity of SFKs might be involved in early invasion of BQ-
induced oral carcinogenesis.
Materials and Methods
BQ Extract and BQ Ingredients’ Extracts Preparations
Betel quid and respective BQ components including AN, IPB, and
SL were obtained from local venders. Water-soluble extracts of BQ
or each component (AN, IPB, or SL) were prepared and optimized
working concentrations were determined as described previously
[21]. Briefly, cells were treated with BQ ingredients for 24 hours,
and cytotoxicity was evaluated by measuring lactate dehydrogenase
activity in culture medium. Working concentration at 0.2 mg/ml for
AN, IPB, or SL has no detectable cytotoxicity.
Cell Culture and Transient Transfection
Oral cancer cell lines Ca9-22, SAS, and SCC9 were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with nutrient mixture F-12 (DMEM/F12; Invitrogen Technologies,
Carlsbad, CA) and 10% FBS. SYF cells, obtained from American
Type Culture Collection (ATCC, Manassas, VA), and mouse embry-
onic fibroblasts (MEFs) were cultured in DMEM supplemented with
10% FBS. For transient transfection, 8 × 105 Ca9-22 cells were seeded
on 60-mm dishes 24 hours before transfection. Afterward, cells were
transfected with pcDNA3.0-HA-CSK or the control vector by using
FuGENE 6 transfection reagent (Roche Applied Science, Indianapolis,
IN). At 36 to 48 hours after transfection, cells were harvested for sub-
sequent migration assay or Western blot analysis.
Plasmid Construction
HA-CSK expression construct was generated by amplifying the
full-length C-terminal Src kinase (CSK) cDNA from astrocytoma
cDNA libraries by polymerase chain reaction using forward (5′-
GAATTCATGTCAGCAATACAGGCCGCC-3′) and reverse (5′-
CTCGAGTCACAGGTGCAGCTCGTG-3′) primers. The cDNA
fragment was cloned into pGEM-T Easy vector (Promega, Madison,
WI), sequenced, and then subcloned into BamHI/XhoI site in the
pcDNA3.0-HA vector.
Migration and Invasion Assays
Toxin A (Clostridium difficile) and PP2 (4-amino-5-(4-chlorophenyl-
7-(t-butyl) pyrazolo [3, 4-d] pyrimidine) were purchased from Cal-
biochem (San Diego, CA). A total of 3 × 104 oral cancer cells in
serum-free culture medium containing toxin A (1 ng/ml), PP2 (2.5-
10 μM), and/or BQ ingredients’ extracts (1.6 or 0.2 mg/ml) were
seeded onto the upper chamber of cell migration inserts with 8.0-μm
pore size polycarbonate membrane (BD Biosciences, San Diego, CA),
and the inserts were then placed into a culturing well containing 10%
FBS medium and treatments as in the upper chamber. Afterward,
cells were allowed to migrate for 24 hours, and nonmigrating cells on
the upper chamber were removed with a cotton swab. Cells that mi-
grated to the lower side of the inserts were fixed with 100% methanol
and stained with Giemsa (Merck, Germany). Cell migration assays for
SYF and MEF cells were performed as described above except that
the seeding cell number was 1 × 104 and migrating period was 3 hours
for MEF and 4 hours for SYF cells. For invasion assays, 1 × 105 cells
were seeded onto the BD BioCoat Matrigel Chambers (BD Biosci-
ences) with the remaining treatments or procedures similar to migration
assays. Totalmigrated or invaded cell number was counted under bright-
field optics at an original magnification of ×100.
Western Blot Analysis
For the detection of ectopic expression of HA-CSK or endogenous
expression of Src family proteins, the transiently transfected cells
were lysed in RIPA buffer [100 mM Tris (pH 8.2), 150 mM NaCl,
1% deoxycholic acid, 1% Triton X-100, 0.1% SDS, and 5 mM
EDTA] supplemented with protease inhibitor cocktail tablets (Roche
Molecular Biochemicals, Mannheim, Germany). Protein concentra-
tions of cell extracts were determined by bicinchoninic acid protein
assay reagent (Pierce, Rockford, IL) using BSA as a standard. Total cell
extracts (12 μg per lane) were resolved on 10% SDS PAGE, followed
by transfer to Immobilon-P PVDF membrane (Millipore, Billerica,
MA). The membranes were probed with anti-HA (Covance, Berkeley,
CA) or anti-Src (Src2; Santa Cruz Biotechnology, Santa Cruz, CA)
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antibody, visualized with enhanced chemiluminescence reagents,
SuperSignal, (Pierce) and underwent autoradiography. For the detec-
tion of endogenous phospho-Src (pY 416), cells were treated with
BQ (1.6 mg/ml) or AN (0.2 mg/ml) extract at various time points
and then lysed directly in 2 × SDS sample buffer. Immunoblot anal-
ysis was carried out as above except that the primary antibody was
anti-Src (pY416; Cell Signaling Technology, Inc., Danvers, MA), and
the incubation was done at 4°C overnight.
In Vitro Kinase Assay
The cellular activity of SFKs treated or untreated with BQ ingre-
dients was detected by in vitro kinase assay as described by Chan
et al. [22] with minor modifications. Src family kinases were immu-
noprecipitated by 5 μg of anti-Src (Src2; Santa Cruz Biotechnology)
and protein A/G–Sepharose beads (Calbiochem) overnight at 4°C.
The immunoprecipitates were then washed thrice with 1% Nonidet
P-40 lysis buffer and twice with 25 mM Tris-HCl, pH 7.4, with
10 mM MnCl2. Later, the beads were incubated with 20 μl of kinase
buffer (50 mM Tris-HCl, pH 7.4, 10 mM MnCl2, 1 mM DTT)
containing 2 μg of acid-denatured enolase (Sigma, St. Louis, MO)
and 10 mCi of [γ-32P]ATP (PerkinElmer Life Sciences, Waltham,
MA) per reaction for 10 minutes at 37°C. Reactions were stopped
by adding Laemmli sample buffer and resolved by SDS-PAGE fol-
lowed by autoradiography.
Tissue Preparation and Immunohistochemistry
Surgical resection specimens including normal mucosa, tumor-
adjacent mucosa, leukoplakia, and squamous cell carcinoma were
obtained from patients undergoing maxillofacial surgery. The In-
stitutional Review Board of National Taiwan University Hospital ap-
proved the use of these tissues. Subsequently, tissues were embedded in
an optimal cutting temperature compound and frozen at −70°C. Fro-
zen tissue sections of 5 μm in thickness were fixed in TBS containing
4% paraformaldehyde for 15 minutes. Endogenous peroxidase was de-
pleted by incubating with 0.3% H2O2 and 10% methanol for 30 min-
utes. Blocking reaction was carried out in TBST containing 10% goat
serum for 60 minutes. Later, tissue sections were first incubated with
anti-Src (pY416; Biosource, Camarillo, CA) at 1:200 dilution in TBST
for 60 minutes at room temperature, followed by washing with
TBST and then incubating with SuperPicture HRP Polymer Con-
jugate secondary antibody (Zymed Laboratories, San Francisco, CA)
for 30 minutes at room temperature. To detect immunoreactivity,
DAB chromagen (Zymed Laboratories) was applied to the tissue sec-
tions until the desired staining intensity was achieved. Sections were
then counterstained with hematoxylin (DAKO, Carpinteria, CA) and
mounted with Entellan (Merck). Interpretations of staining results
were performed by a pathologist from the Department of Pathology
at the National Taiwan University Hospital.
Semiquantitation of Src (pY416) Immunoreactivities
and Statistics
Immunoreactivities were quantified with a 12-point weighted score
[23]. First, the percentage of positive staining in each section was
scored with a 5-point scale: 0 for <5%, 1 for 5% to 25%, 2 for
25% to 50%, 3 for 50% to 75%, and 4 for >75%. Second, the
intensity of positive staining was scored with a 3-point scale: 1 for
weak, 2 for medium, and 3 for strong. The weighted score for each
section was obtained by adding the percentage score and the inten-
sity score. The staining intensity was compared to that in colon can-
cer sections, which served as the positive control, and was scored as
3. Correlations between immunoreactivities for tumor-adjacent mu-
cosa sections and those for the remaining tissue categories were cal-
culated by using an independent two-population t test. Significance
was defined at P < .05. Graphing and statistics were plotted by
Microcal Origin 6.0 software.
Results
Betel Quid Extract Induces Oral Cancer Cell Migration
through SFKs-Mediated Signaling Pathways
To test the hypothesis that BQ extract might increase oral cancer
cell motility through certain cellular signaling pathway(s), oral cancer
cells Ca9-22 were treated with BQ extract while being allowed to
migrate for 24 hours in a Boyden’s chamber–based apparatus. Treat-
ing Ca9-22 cells with BQ extract at 1.6 mg/ml, the optimal working
concentration determined by cytotoxicity [21], resulted in a dramatic
six-fold increase in cell migration. Because the SFKs and the Rho
family GTPase are the two central cellular signalings implicated in
cell migration, we asked whether PP2 and toxin A (C. difficile),
the two respective selective inhibitors of the aforementioned signal-
ing pathways, could act against the observed BQ-induced cell migra-
tion. Interestingly, our findings revealed that PP2, but not toxin A,
could considerably counteract BQ-induced cell migration, raising the
possibility that BQ extract might enhance cancer cell motility
through selective activation of SFKs (data not shown). To exclude
serendipity, we examined whether BQ-induced cell migration could
be observed in additional oral cancer cells and how BQ-treated can-
cer cells responded to increasing concentrations of PP2 (2.5-10 μM).
We found that BQ extract could evidently increase cell migration in
all three oral cancer cell lines, whereas this was counteracted by PP2
in a dose-dependent manner (Figure 1A). To confirm this result, an
expression vector carrying CSK, the cellular-negative regulator of
SFKs instead of a synthetic inhibitor such as PP2, was introduced
into Ca9-22 cells followed by allowing cell migration in the presence
or absence of BQ extract. Ectopic overexpression of Csk reduced
BQ-induced cell migration by about two-fold (Figure 1B). These re-
sults suggest that BQ extract can significantly increase oral cancer cell
motility presumably through SFKs-mediated signaling pathways.
Requirement of SFKs for BQ-Induced Cell Migration
The fact that PP2 effectively antagonizes the increased cell mi-
gration brought about by BQ stimulation prompted us to address
whether SFKs are required for BQ-induced cell migration. To this
end, we sought to demonstrate the necessity of SFKs for BQ-induced
cell migration using SYF cells, an MEF lacking all three ubiquitously
expressed Src family members, namely, Src, Fyn, and Yes. Our results
showed that, in the presence of BQ, cell migration was notably in-
creased in MEFs, the legitimate wild type control cells. In contrast,
treating SYF cells with BQ extract exhibited negligible effects on cell
migration (Figure 2A). To confirm whether BQ-induced MEF cell
migration could be attributable to the activation of SFKs, we inves-
tigated the phosphorylation status of tyrosine 416 (pY416), because
autophosphorylation at this residue of the catalytic domain is a pu-
tative indicator of cellular activity of SFKs [24]. Immunoblot analy-
sis results indicated an increase in pY416 after treating MEF cells
with BQ extract for 30 minutes or longer, thereby suggesting en-
hanced kinase activities. More importantly, protein expression of
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SFKs, as revealed by a “pan-Src” antibody (Src2), remained virtually
unchanged on BQ stimulation (Figure 2B). As expected, both protein
expressions of SFKs and kinase activities were not detectable in SYF
cells (data not shown). These findings indicate that BQ extract can
induce cell migration through elevating the kinase activity but not
regulating the protein expression of endogenous SFKs.
Betel Quid Extract Stimulates the Cellular Activity of SFKs in
Oral Cancer Cells
To provide direct evidence that BQ extract can activate SFKs in
oral cancer cells, leading to an overt increase in cell motility, we like-
wise checked Src (pY416) in BQ-treated Ca9-22 cells. We found that
SFK activities were persistently activated for at least 1 hour during a
time-course BQ treatment, whereas, resembling the results in MEF
cells, the protein expression level was constant throughout the treat-
ment period (Figure 3A). We then confirmed whether the elevated ki-
nase activity was caused by the stimulation of BQ extract by in vitro
kinase assay. Immunoprecipitates of SFKs from BQ-treated cell ly-
sates were used for measuring the capacity of tyrosine phosphoryla-
tion of an in vitro substrate, enolase. Treatment of Ca9-22 cells with
BQ extract resulted in a pronounced increase in both SFK autophos-
phorylation and kinase activities (Figure 3B), indicating that BQ
could truly stimulate the cellular activity of SFKs, which was further
validated by their elevated catalytic activities in vitro. These, in con-
junction with the previous results in which PP2 profoundly counter-
acts BQ-induced cell migration, have clearly proven that BQ extract
can stimulate oral cancer cell motility through the activation of SFKs.
Areca Nut Is the Major Component Responsible for
BQ-Induced Biologic Effects
Having demonstrated that BQ extract, the whole mixture of the
three major components AN, IPB, and SL, could activate SFKs and
thereby cancer cell motility, it was tantalizing to determine which
component is likely to be the key factor for these biologic effects.
We directly tested the ability of each component to promote cell
migration of Ca9-22 cells. We found, remarkably, that under the
same treatment concentration (0.2 mg/ml), AN extract enhanced
cell migration by about three-fold, whereas IPB and SL extracts had
Figure 1. Betel quid extract induces oral cancer cell migration through activation of SFKs. (A) Cell migration of three oral cancer cell lines
Ca9-22, SAS, and SCC9 was all significantly induced when treated with BQ extract (1.6 mg/ml), as indicated by the increased total
migrated cell numbers. The elevated cell motility could be progressively counteracted by addition of an increasing concentration of
PP2 (2.5-10 μM). Each treatment contains DMSO, the solvent of PP2, for control purpose. (B) Ectopic overexpression of the cellular-
negative regulator of SFKs, CSK, resulted in reduced cell migration in the presence of BQ extract. Ca9-22 cells were transfected with
HA-CSK construct or control vector, and protein expression was confirmed by Western blot analysis as shown. All migration assays
were done in triplicates, and results were expressed as mean ± SD.
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negligible effects (Figure 4A). In addition, the control experiment
represented by an irrelevant substance sucrose excluded possible ser-
endipity associated with AN-induced cell migration. To verify whether
AN-induced cell migration was also mediated through SFK signaling
pathways, we examined AN-induced cell migration in the presence
of increasing concentrations of PP2. As anticipated, PP2 seemed to
act against AN-induced cell migration in a dose-dependent manner,
consistent with its effects on BQ-induced cell motility (Figure 4B).
Moreover, in a time-course treatment with AN extract, cellular SFK
activities were elevated as indicated by an increase in Src (pY416),
whereas endogenous protein expression remained unchanged through-
out the treatment period (Figure 4C). Likewise, AN-induced SFK ac-
tivities were further confirmed by in vitro kinase assay as described
(Figure 4D). Collectively, these findings have identified AN as the
major component contributing to BQ-induced oral cancer cell migra-
tion through SFKs-mediated signaling pathways.
SFKs Mediate BQ- and AN-Enhanced Oral Cancer
Cell Invasion
We next tested whether BQ or AN extract can induce oral cancer
cell invasion in vitro. Betel quid- or AN-treated Ca9-22 cells were
seeded onto invasion chambers to assess their ability to pass through
a thin layer of Matrigel membrane. In good agreement with previous
migration assays, we found that both BQ and AN extracts can induce
cell invasion by about three- and two-fold, respectively. Conversely,
because PP2 seemed to significantly inhibit cell invasion in the pres-
ence of BQ or AN extract, we thus confirmed that BQ and AN ex-
tracts conferred this enhanced invasive property by activating the
SFK signaling pathway (Figure 5, A and B).
Activity of SFKs May Be Important for Oral Cancer Cell
Invasion In Vivo
To explore the possibility that SFKs could be a biomarker for tu-
mor invasion and/or metastasis in clinicopathologic conditions, oral
tissue sections containing healthy mucosa without BQ exposure,
corresponding tumor-adjacent mucosa, leukoplakia (or commonly
deemed “precancer”), and tumor (OSCC) [21] were subjected to im-
munohistochemical staining using anti-Src (pY416). Consistent with
the in vitro results, BQ-chewing oral cavity lesions including 2/4 of
leukoplakia, 14/14 of tumor-adjacent mucosa, and 7/16 of OSCC
had positive staining, whereas all of BQ-free healthy oral mucosa
had negative staining (Figure 6, A–D). These results have confirmed
the induction of SFK activities by BQ in clinical tissues. Conversely,
the activity of SFKs also increased in both BQ-free tumor-adjacent
mucosa (17/19) and OSCC (6/19; Figure 6, E and F ). Because it
seemed that SFKs might not be activated exclusively by BQ, we then
compared the staining of Src (pY416) among the four categories of
oral tissue specimens regardless of BQ-chewing. Our results indicate
that the average weighted scores for Src (pY416) immunoreactivities
Figure 2. Betel quid–induced cell migration was abolished in SFK-
deficient cells. (A) Wild type MEFs and SYF, MEF cells lacking Src,
Yes, and Fyn, were treated with BQ extract while being allowed
to migrate for 3 hours and 4 hours, respectively. Betel quid ex-
tract could induce cell migration of MEF cells by about seven-fold,
whereas no induction was observed in SYF cells. (B) Mouse em-
bryonic fibroblast cells were treated with BQ extract for various
periods as indicated, and phosphorylation of Src (pY416) was de-
termined using Western blot analysis. Phosphorylation of SFKs at
tyrosine 416 (Src 416) was increased in MEF cells 30 minutes after
BQ extract treatment. Anti-SFKs antibody (Src2) detected total pro-
teins of SFKs. GAPDH was the loading control.
Figure 3. Enhancement of SFK activities by BQ extract in oral
cancer cell Ca9-22. (A) Ca9-22 cells were treated with BQ extract
for different periods as indicated and subjected to detection of
phospho-Src (pY416) as described in Figure 2B. Phosphorylation
at tyrosine 416 was quickly induced within 5 minutes on BQ stim-
ulation. (B) The cellular activity of SFKs treated or untreated with
BQ ingredients was detected by in vitro kinase assay. Ca9-22 cells
were treated with BQ extract for 30 minutes and then the cell ly-
sates were immunoprecipitated with anti-SFKs antibody (Src2).
Cellular Src kinase activities were directly measured on protein A/G
agarose beads carrying Src immunocomplex. In the presence of
BQ, Src kinases autophosphorylation was significantly increased,
leading to increased phosphorylation of the in vitro substrate, eno-
lase (arrows).
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in tumor-adjacent mucosa, leukoplakia, and OSCC were generally
higher than in healthy mucosa. Interestingly, we found that the av-
erage weighted score of tumor-adjacent mucosa was significantly
higher than that of healthy mucosa (P = 3.68e−5), leukoplakia (P =
4.47e−4), and OSCC (P = 2.34e−10), respectively (Figure 6G ).
These data indicate that the activity of SFKs may be involved mostly
in early invasion when neoplastic cells begin to invade adjacent nor-
mal tissues. In addition, despite its diminished activity at OSCC
Figure 4. Areca nut is the key component of BQ that induces oral cancer cell migration through activation of the SFKs. Water-soluble ex-
tracts of BQ ingredients including AN, IPB, and SL were prepared, and optimal working concentrations were determined as described.
(A) Ca9-22 cells were treated with the respective BQ components at an identical concentration (0.2 mg/ml) and migration assays were per-
formedasabove. Sucrosewas the irrelevant substancecontrol. (B) Areca nut–inducedoral cancer cellmigrationwas further examinedaswas
done in Figure 1A, in that the concentration of AN extract was 0.2 mg/ml and PP2 was 2.5 to 10 μM. (C) Induction of phosphorylation at
tyrosine 416 (Src416) at different time points by AN extract (0.2 mg/ml) was detected as previously described. The asterisk indicates a
30-minute period of BQ extract treatment on Ca9-22 cells. (D) Ca9-22 cells were treated with AN extract (0.2 mg/ml) for 30 minutes and then
cellular Src kinase activities were directly measured on protein A/G–Sepharose beads carrying Src immunocomplex by in vitro kinase assay.
Figure 5. The BQ and AN extracts induce oral cancer cell invasion through SFKs-mediated signaling pathways. (A) Cell invasion of Ca9-
22 cells was assayed using Matrigel-coated invasion chambers with different treatments as indicated. Cells were allowed to invade
through the Matrigel membrane for 22 hours and then total invaded cell numbers were counted. Invasion assays were done in tripli-
cates, and results were expressed as mean ± SD. (B) Representative fields of invaded cells corresponded to the invasion assay in (A).
Original magnification, ×100.
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compared to tumor-adjacent mucosa, the staining of Src (pY416) is
localized at the invasion front of both BQ-chewing and BQ-free
OSCC, suggesting that the activity of SFKs is necessary for tumor
cells to invade the neighboring stromal tissues (Figure 6, H and I ).
Discussion
The SFKs play a central role in a variety of signal transduction
pathways, regulating fundamental cellular processes including cell
growth, differentiation, adhesion, motility, angiogenesis, and survival
[25,26]. In addition, SFKs have been implicated in the development
of many different types of human cancers [27,28]. Of particularly
importance is the intimate correlation between the three widely ex-
pressed members Src, Fyn, and Yes and malignant phenotypes such
as tumor invasion and metastasis [29]. For example, elevated Src pro-
tein expression and/or activity have been linked to high metastatic
potential in colon and in many other epithelial cancers [30,31]. More
importantly, compounds targeting SFKs have been evaluated in pre-
clinical models for treatment of solid tumors including head and
neck squamous cell carcinoma [32]. To date, BQ-chewing oral cancer
has had a serious impact on especially male health of Southeast
countries despite an increasing research effort. Indeed, it is conceivable
Figure 6. Immunohistochemical and statistical analyses of SFKs in oral tissue sections. Representative results of immunohistochemical
staining of Src (pY416) in (A) BQ-free healthy mucosa, (B) BQ-chewing leukoplakia, (C) BQ-chewing tumor-adjacent mucosa, (D) BQ-
chewing OSCC, (E) BQ-free tumor-adjacent mucosa, and (F) BQ-free OSCC. (G) Average weighted scores ± SD of Src (pY416) immu-
noreactivities for the four categories of oral tissue specimens. Score distribution of samples in each category was denoted by solid
diamonds (♦), whereas statistical difference by P values. Immunohistochemical staining of Src (pY416) at the invasion front of (H)
BQ-chewing and (I) BQ-free OSCC. Microscopic magnification was ×200 in all cases.
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that a lack of understanding on the precise mechanism behind the
multistep chemical carcinogenesis including invasion or metastasis
has prevented a breakthrough in clinical therapeutics.
In the present study, to better simulate tumor cell movement in a
three-dimensional microenvironment in vivo, we used Boyden’s
chamber–based apparatus to analyze the effects of BQ and its com-
ponents on in vitro oral cancer cell migration and invasion. Although
the Rho family GTPase has been well implicated in cancer cell
migration and invasion [33,34], BQ-induced cancer cell migration
is selectively and effectively inhibited by PP2 but not toxin A, the
specific inhibitor of Rho GTPases. Moreover, we showed that BQ-
induced cell migration in MEFs necessitates SFKs. These results
suggest that BQ-induced cell migration is primarily triggered by
SFKs-mediated signaling pathways. However, activation of SFKs
seems to be delayed in MEFs compared to that in oral cancer cells,
suggesting that BQ can induce distinct signaling pathways in differ-
ent cell types. It is noteworthy that SFKs can promptly respond to
BQ stimulation while their protein expressions remain nearly con-
stant during the treatment period, raising the possibility that this
BQ-induced biologic effect is unlikely to involve gene regulation nor-
mally taking place in the nucleus. Furthermore, we identified that
AN is the key ingredient contributing to BQ-induced cell migration
and invasion through the activation of SFKs. However, the fact that
BQ, but not AN, can significantly promote cell motility may thus
suggest a synergistic effect of the heterogeneous BQ compositions
on cell motility. It is possible that this synergistic effect can activate
additional signaling pathways different from those induced by AN.
In addition, whether arecoline and arecaidine, the two major alka-
loids of AN, can induce similar biologic effects is currently unknown.
Verification of this should further potentiate clinical and therapeu-
tic applications.
The activity of SFKs induced by BQ extract in cultured cells was
recapitulated in BQ-chewing oral cavity lesions including leukoplakia,
corresponding tumor-adjacent mucosa, and OSCC. However, de-
spite relatively weak Src (pY416) immunoreactivities, we found that
SFK activities were also elevated in BQ-free tumor-adjacent mucosa
and OSCC specimens. These results indicate that etiologic factors
except BQ chewing may induce SFK activities in clinicopathologic
cases. Indeed, a recent study showed that nicotine, a component of
cigarette smoke, could increase phospho-Src (pY416) level and thus
the activity of SFKs [35]. Whereas clinicopathologic parameters other
than BQ chewing for these BQ-free tissue specimens are uncertain,
we nonetheless speculate that persistent smoking and alcohol drink-
ing, two popular habits frequently associated with BQ chewing in
local populations, are likely to stimulate SFK activities in tissues of
oral cavity. Moreover, regardless of BQ chewing, the three categories
of oral cavity lesions seemed to have elevated average weighted scores
for Src (pY416) immunoreactivities, in that, surprisingly, the activity
of SFKs (or average weighted score) in tumor-adjacent mucosa was
significant higher than that in leukoplakia and OSCC. These results
have raised an intriguing possibility that SFK activities could play an
important role in early invasion, during which invasive cancer cells
begin to migrate from the primary tumor site into the surrounding
normal tissues. This is consistent with a most recent study, in that
the tumor-host interface has the highest activity of SFKs, which trig-
gers invasion of glioblastoma in vivo. In contrast, a reduced activity of
SFKs was found in the inner tumor mass [36]. Interestingly, we also
found that the activity of SFKs was increased in vitro by BQ extract
in normal human oral keratinocytes (data not shown), which may
support the observation that SFK activities are significantly higher
in BQ-chewing than in BQ-free tumor-adjacent mucosa (Figure 6,
C and E ). Besides, we demonstrated that SFKs activities were located
at the invasion front of OSCC, suggesting a possible function of
SFKs in basement membrane penetration and stromal invasion inside
the tumor mass.
The molecular mechanism underlying BQ-induced SFKs activa-
tion is still unclear. It has been shown that AN extract does not ac-
tivate EGFR in oral keratinocytes [13]. Consistent with this result are
our preliminary data suggesting an unlikely role of EGFR in BQ-
induced cell migration because of a lack of inhibition on this biologic
effect when EGFR inhibitor is present. Whether BQ ingredients can
activate motility-promoting signaling pathways including SFKs in an
EGFR-independent manner is under investigation. Likewise, it re-
mains elusive what additional downstream signaling molecules or ef-
fectors might bridge between the relatively upstream BQ-induced
SFK activities and the finally displayed biologic effects. A recent re-
port by others indicates that AN extract can activate mitogen-activated
protein kinases such as c-Jun N-terminal kinase and the stress-
regulated transcription factor NF-κB [13]. However, whether these
AN-activated signaling pathways are directly linked to biologic func-
tions of oral cancer cells is still unknown. Thus, our current studies
have been aimed to globally identify cellular signaling pathways
mediating BQ-induced cancer cell motility. Another important ques-
tion to address is whether the SFKs including Src, Yes, and Fyn could
be differently stimulated by BQ or AN, thereby to various extents
modulating BQ- or AN-induced oral cancer motility. Our prelimi-
nary results suggest that Src kinase activity per se plays a role in
BQ-induced cell motility, yet the detailed mechanism requires fur-
ther studies.
In conclusion, we have shown that BQ extract can significantly
induce in vitro oral cancer cell motility, including migration and in-
vasion, through the activation of SFKs. Given that BQ generally
comprises AN, IPB, and SL, we further dissected the effects of these
major components and found that AN seemed to be the sole com-
ponent that dramatically enhanced cell motility. More importantly,
our results also reveal that such AN-induced cell motility can be
largely mediated by SFKs, too. Finally, taking together our in vitro
and immunohistochemical studies, we propose that SFKs could be
a potential biomarker for cancer cell motility and tumor invasion
of oral carcinogenesis. More importantly, considering the therapeutic
perspectives, we have validated SFKs a potential target for the devel-
opment of antimigratory compounds against oral cancer. Verifica-
tions by other in vitro cell migration assays [37] should further
warrant its clinical applications.
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